MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer

The p53 gene and MDM2 gene play critical roles in cell cycle arrest and apoptosis together. Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms. Totally 1,193 cases and 1,310 age frequency-matched controls were included in the study. Prostate cancer patients were followed to determine the intervals of overall survival and disease-free survival. The Pro(72)Arg Pro allele (homozygous and heterozygous) were significantly associated with prostate cancer risk with an odds ratio (OR) of 0.77 [95% confidence interval (CI), 0.64-0.93]. SNP309 T alleles were associated with a significantly decreased prostate cancer risk among Pro(72)Arg Pro alleles carriers (OR=0.79, 95% CI, 0.64-0.98). In addition, compared with the Pro(72)Arg Pro alleles and SNP309 G homozygous, patients carrying both SNP309 T alleles and Pro(72)Arg Arg homozygous had more favorable disease-free survival (hazard ratio [HR] = 0.59, 95% CI, 0.38-0.93). Our results indicated that SNP309 and Pro(72)Arg polymorphisms may jointly contribute to the etiology and prognosis of prostate cancer.